Literature DB >> 26770396

Analysis on the metabolite composition of serum samples from patients with papillary thyroid carcinoma using nuclear magnetic resonance.

Wen-Xin Zhao1, Bo Wang1, Li-Yong Zhang1, Shou-Yi Yan1, Ying-Hong Yang2.   

Abstract

OBJECTIVE: Analysis of the metabolic differences among the papillary thyroid carcinoma (group T) patients, benign thyroid tumor patients (group B) and healthy controls (group H) by nuclear magnetic resonance hydrogen spectrum.
METHODS: collect twenty serum specimens each from group T, group B and group H. Collect image archive. Use Topspin software, AMIX software and SIMCA-P+ software to calibrate, integrate with PCA and PLS-DA, research the three groups' serum for endogenous metabolic differences.
RESULTS: The data of group T and group H established a discrimination model, and the model is correct (P<0.05). The content of metabolites in the serum of team T increased including valine, leucine, isoleucine, lactic acid, alanine, glutamic acid, lysine, glycine, while the lipids, choline, tyrosine decreased. The data of group B and group H established a discrimination model and the model is correct (P<0.05). The content of metabolites in the serum of team B increased including Trimethyl glycine, tyrosine, phenylalanine, valine, leucine, isoleucine, lactic acid, alanine, glutamic acid, while the Lipids and lysine reduced.
CONCLUSION: Compared with team H, there is an obvious metabolic difference in team T and team B. It not only involves glucose metabolism but also the metabolism of lipids, amino acids and nucleic acid.

Entities:  

Keywords:  Thyroid neoplasms; metabonomics; principal component analysis

Year:  2015        PMID: 26770396      PMCID: PMC4694296     

Source DB:  PubMed          Journal:  Int J Clin Exp Med        ISSN: 1940-5901


  26 in total

1.  Ultrasound guided fine-needle aspiration biopsy of thyroid nodules: Guidelines and recommendations vs clinical practice; a 12-month study of 89 patients.

Authors:  M Peli; E Capalbo; M Lovisatti; M Cosentino; E Berti; R Mattai Dal Moro; M Cariati
Journal:  J Ultrasound       Date:  2012-01-05

2.  Fine needle aspiration biopsy of follicular thyroid tumors.

Authors:  Biljana Pauzar; Blazenka Staklenac; Branka Loncar
Journal:  Coll Antropol       Date:  2010-03

3.  Tissue inhibitor of metalloproteinase-3 (TIMP-3) gene is methylated in the development of esophageal adenocarcinoma: loss of expression correlates with poor prognosis.

Authors:  S Jane Darnton; Laura J Hardie; Ronald S Muc; Christopher P Wild; Alan G Casson
Journal:  Int J Cancer       Date:  2005-06-20       Impact factor: 7.396

4.  Metabolomics study of esophageal adenocarcinoma.

Authors:  Jian Zhang; Lingyan Liu; Siwei Wei; G A Nagana Gowda; Zane Hammoud; Kenneth A Kesler; Daniel Raftery
Journal:  J Thorac Cardiovasc Surg       Date:  2010-09-28       Impact factor: 5.209

Review 5.  Targeting DNA methylation in cancer.

Authors:  Moshe Szyf
Journal:  Ageing Res Rev       Date:  2003-07       Impact factor: 10.895

6.  High recurrent rate of multicentric papillary thyroid carcinoma.

Authors:  Jen-Der Lin; Tzu-Chieh Chao; Chuen Hsueh; Sheng-Fong Kuo
Journal:  Ann Surg Oncol       Date:  2009-06-16       Impact factor: 5.344

7.  Down-regulation and promoter methylation of tissue inhibitor of metalloproteinase 3 in choriocarcinoma.

Authors:  Huichen Feng; Annie N Y Cheung; Wei-Cheng Xue; Yanling Wang; Xianghong Wang; Songbin Fu; Qi Wang; Hextan Y S Ngan; Sai-Wah Tsao
Journal:  Gynecol Oncol       Date:  2004-08       Impact factor: 5.482

Review 8.  Mutant metabolic enzymes are at the origin of gliomas.

Authors:  Hai Yan; Darell D Bigner; Victor Velculescu; D Williams Parsons
Journal:  Cancer Res       Date:  2009-12-15       Impact factor: 13.312

9.  Epigenetics modifications and therapeutic prospects in human thyroid cancer.

Authors:  Maria Graziella Catalano; Nicoletta Fortunati; Giuseppe Boccuzzi
Journal:  Front Endocrinol (Lausanne)       Date:  2012-03-19       Impact factor: 5.555

10.  Thyroid fine-needle aspiration biopsy and thyroid cancer diagnosis: a nationwide population-based study.

Authors:  Li-Ying Huang; Ya-Ling Lee; Pesus Chou; Wei-Yih Chiu; Dachen Chu
Journal:  PLoS One       Date:  2015-05-28       Impact factor: 3.240

View more
  5 in total

Review 1.  Nuclear magnetic resonance spectroscopy as a new approach for improvement of early diagnosis and risk stratification of prostate cancer.

Authors:  Bo Yang; Guo-Qiang Liao; Xiao-Fei Wen; Wei-Hua Chen; Sheng Cheng; Jens-Uwe Stolzenburg; Roman Ganzer; Jochen Neuhaus
Journal:  J Zhejiang Univ Sci B       Date:  2017 Nov.       Impact factor: 3.066

2.  RNA-sequencing investigation identifies an effective risk score generated by three novel lncRNAs for the survival of papillary thyroid cancer patients.

Authors:  Yi-Huan Luo; Liang Liang; Rong-Quan He; Dong-Yue Wen; Guo-Fei Deng; Hong Yang; Yun He; Wei Ma; Xiao-Yong Cai; Jun-Qiang Chen; Gang Chen
Journal:  Oncotarget       Date:  2017-05-26

Review 3.  Oncometabolites as biomarkers in thyroid cancer: a systematic review.

Authors:  Fatemeh Khatami; Moloud Payab; Masoumeh Sarvari; Kambiz Gilany; Bagher Larijani; Babak Arjmand; Seyed Mohammad Tavangar
Journal:  Cancer Manag Res       Date:  2019-02-25       Impact factor: 3.989

Review 4.  The Potential of Metabolomics in the Diagnosis of Thyroid Cancer.

Authors:  Margarida Coelho; Luis Raposo; Brian J Goodfellow; Luigi Atzori; John Jones; Bruno Manadas
Journal:  Int J Mol Sci       Date:  2020-07-24       Impact factor: 5.923

5.  Characterization of Lactate Metabolism Score in Breast and Thyroid Cancers to Assist Immunotherapy via Large-Scale Transcriptomic Data Analysis.

Authors:  Cheng Wang; Zheng Qu; Li Chen; Yunhao Pan; Yiqing Tang; Guangfu Hu; Ran Gao; Ruijie Niu; Qiang Liu; Xingyan Gao; Yi Fang
Journal:  Front Pharmacol       Date:  2022-07-07       Impact factor: 5.988

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.